TW202302526A - Ｍｅｋ抑制劑ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之結晶固體及其用途 - Google Patents

Ｍｅｋ抑制劑ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之結晶固體及其用途 Download PDF

Info

Publication number
TW202302526A
TW202302526A TW111105779A TW111105779A TW202302526A TW 202302526 A TW202302526 A TW 202302526A TW 111105779 A TW111105779 A TW 111105779A TW 111105779 A TW111105779 A TW 111105779A TW 202302526 A TW202302526 A TW 202302526A
Authority
TW
Taiwan
Prior art keywords
crystalline form
fluoro
difluoro
dihydroxypropoxy
phenylamino
Prior art date
Application number
TW111105779A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯汀 派特森
吉平 劉
瑞基 偉恩 科曲
彼得 格雷戈里 瓦拉司金
美 李
永宏 甘
Original Assignee
美商斯普林渥克斯治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商斯普林渥克斯治療有限公司 filed Critical 美商斯普林渥克斯治療有限公司
Publication of TW202302526A publication Critical patent/TW202302526A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
TW111105779A 2021-02-17 2022-02-17 Ｍｅｋ抑制劑ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之結晶固體及其用途 TW202302526A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2021/018381 WO2022177557A1 (en) 2021-02-17 2021-02-17 Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
WOPCT/US21/18381 2021-02-17

Publications (1)

Publication Number Publication Date
TW202302526A true TW202302526A (zh) 2023-01-16

Family

ID=74860569

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105779A TW202302526A (zh) 2021-02-17 2022-02-17 Ｍｅｋ抑制劑ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之結晶固體及其用途

Country Status (10)

Country Link
EP (1) EP4294526A1 (ja)
JP (1) JP2024509759A (ja)
KR (1) KR20230147139A (ja)
CN (1) CN117083264A (ja)
AR (1) AR124911A1 (ja)
AU (1) AU2021428512A1 (ja)
CA (1) CA3207513A1 (ja)
IL (1) IL305078A (ja)
TW (1) TW202302526A (ja)
WO (1) WO2022177557A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023223205A1 (en) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Solid state forms of mirdametinib and process for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1301472T1 (sl) 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
NZ546011A (en) 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
US11066358B1 (en) * 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) * 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

Also Published As

Publication number Publication date
EP4294526A1 (en) 2023-12-27
AU2021428512A1 (en) 2023-09-21
WO2022177557A1 (en) 2022-08-25
AR124911A1 (es) 2023-05-17
CN117083264A (zh) 2023-11-17
KR20230147139A (ko) 2023-10-20
IL305078A (en) 2023-10-01
CA3207513A1 (en) 2022-08-25
JP2024509759A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
US11084780B1 (en) Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11312700B2 (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11453641B2 (en) Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
TW201000471A (en) Trisubstituted 1,2,4-triazoles
EP2991999A1 (en) Co-crystals of dapagliflozin
TW200825074A (en) Compounds
TW202302526A (zh) Ｍｅｋ抑制劑ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之結晶固體及其用途
US11571402B2 (en) Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
CN117769540A (zh) 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
US20090292025A1 (en) Novel crystalline forms of armodafinil and preparation thereof
CN109843300B (zh) 一种化合物的结晶多晶型形式
TW202245746A (zh) Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途
TW202245745A (zh) Ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之可分散調配物及其用途
US8471032B2 (en) Benzimidazole compound in crystal form and salt thereof
US20220089550A1 (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)-n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
TW201034673A (en) Novel salt of 1,3,5-triazine-2,4,6-triamine derivative
CN112759545A (zh) 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
TW201011016A (en) New compounds 501
TW201011015A (en) New compounds 500